6533b826fe1ef96bd12848e2

RESEARCH PRODUCT

Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis

Fabio RaitiAlessandra BattagliaVincenzo AdamoMaria PicciottoGiuseppe ToscanoSerena SavaAntonio RussoA. Scimone

subject

Oncologymedicine.medical_specialtybusiness.industryLymphocytenon-small cell lung cancer (NSCLC)Hematology030204 cardiovascular system & hematologyNSCLCmedicine.diseasePreliminary analysis03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureOncologyDocetaxel030220 oncology & carcinogenesisInternal medicinemedicineAbsolute neutrophil countPlateletNeutrophil to lymphocyte ratioNivolumabbusinessmedicine.drug

description

Nivolumab (N) is a novel therapeutic option in NSCLC, with a significant survival gain compared with Docetaxel (D). However, predictive biomarkers are lacking and no strategies have been adopted to date for optimal patients (pts) selection. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response in pts treated with N or D.

yearjournalcountryeditionlanguage
2017-10-01Annals of Oncology
https://doi.org/10.1093/annonc/mdx426.021